MedImmune to Acquire Amplimmune (Photo)AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology.
The buyout is designed to strengthen MedImmune’s cancer-related research, and includes an initial payment of $225 million, with the possibility of another $275 million if certain development milestones are reached.
“MedImmune’s focus on harnessing the power of the patient’s own immune system to fight cancer will be complemented by Amplimmune’s innovative work in this area. It will allow us to strengthen our arsenal of potential cancer therapies,” said Dr. Bahija Jallal, Executive Vice President of MedImmune. “We are excited to be working with the Amplimmune team to help find new treatments to address areas of unmet medical need.”
“Both companies are passionate about developing new cancer therapies for patients and are excited about the potential of immunotherapies. We are pleased to be joining MedImmune, who will work to further advance the pioneering work we’ve been conducting in this area,” said Michael Richman, Amplimmune’s President and Chief Executive Officer. “The synergy achieved by combining our pipelines provides an important path towards developing novel immunotherapy products.”
Amplimmune has been in the city of Gaithersburg since its move from Rockville in 2011. Gaithersburg officials awarded it a $50,000 toolbox grant to support the renovation of 20,570 square feet of space on West Watkins Mill Road, including interior demolition and the construction of new office space, lab space and manufacturing facilities. At the time of the application Amplimmune employed 23 people.
“These are the kind of success stories we love to hear,” said Tom Lonergan, Gaithersburg’s economic development director. “Our grants are designed to provide the basis for growth and innovation, and Amplimmune serves as an excellent example of that. From lab space fit ups to employee training to signage, Toolbox grants help lay the foundation for future success.”
For more information on the MedImmune acquisition, visit www.medimmune.com/media.
The Johns Hopkins University and MedImmune announced this week a first-of-its-kind Ph.D. training program between a major university and a biopharmaceutical company in the United States. Known as the Johns Hopkins-MedImmune Scholars Program, this new initiative will build on an ongoing collaboration between MedImmune and Johns Hopkins, and reinforces both partners’ commitment to grow the […]
Here are your five things to know today, Oct. 15, in Montgomery County: 1. Crews are finishing road repairs at the scene of Tuesday’s water main break at Rockville Pike and Cedar Lane. According to WSSC, all southbound lanes should be open by 8 a.m. today. All northbound lanes are already open. 2. The Maryland […]
The Gaithesburg City Council and Planning Commission will hold a joint public hearing at 7:30 p.m. on July 20th to discuss a schematic development plan (SDP) application for construction of a structured parking garage on the MedImmune/Astrazeneca campus. The proposed parking garage would include 1,386 spaces to serve future development on the company’s Gaithersburg campus. […]
UPDATED MedImmune and AstraZeneca officials are planning to build a child care center adjacent to the company’s corporate campus at One MedImmune Way in Gaithersburg. In an email sent on Feb. 11, the biotech company alerted Quince Orchard Park community residents that a Schematic Development Plan (SDP) application for construction of the child care center […]
Six members of the Maryland Congressional delegation have written to Pfizer CEO Ian Read concerning the company’s potential acquisition of AstraZeneca, which employs over 3,000 in Maryland. The letter was led by Congressman John K. Delaney (MD-6) whose district includes the Gaithersburg headquarters of AstraZeneca subsidiary MedImmune. The letter was signed by Senator Barbara A. […]
Maryland Governor Martin O’Malley and Deleware Governor Jack Markell sent a letter today to Ian Read, chairman and Chief Executive Officer of Pfizer, Inc., expressing deep concerns about the potential acquisition of AstraZeneca PLC. The letter highlights the potentially significant impact on good, family-sustaining jobs in both Maryland and Delaware, and expresses concern about the […]
Gaithersburg based MedImmune, the global biologics research and development arm of AstraZeneca, announced Nov. 14 that Yong-Jun Liu, M.D., Ph.D. has been named the company’s new head of research, effective Jan. 6, 2014. Dr. Liu currently serves as vice president and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute […]
AstraZeneca announced (Oct. 30) the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company’s global biologics research and development arm. The goal of CALIMA, the first study in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients […]
MedImmune, completed its acquisition of Amplimmune, a privately-held, Gaithersburg based biologics company focused on developing novel therapeutics in cancer immunology. MedImmune acquired 100% of Amplimmune’s shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching established development milestones. Founded in 2007 and headquartered in Gaithersburg, Amplimmune […]
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology. The buyout is designed to strengthen MedImmune’s cancer-related research, and includes an initial payment of $225 million, with the possibility of another […]